TITLE

Fixed-Dose Combination Lercanidipine/Enalapril

AUTHOR(S)
Hair, Philip I.; Scot, Lesley J.; Perry, Caroline M.
PUB. DATE
January 2007
SOURCE
Drugs;2007, Vol. 67 Issue 1, p95
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
▴ Lercanidipine, a dihydropyridine calcium channel blocker, and enalapril, an ACE inhibitor, are established antihypertensive agents. A fixed-dose tablet formulation of lercanidipine/enalapril is approved in Germany for the treatment of hypertension in patients not responding to monotherapy.▴ Lercanidipine/enalapril 10mg/10mg once daily significantly reduced sitting diastolic blood pressure and sitting systolic blood pressure, relative to lercanidipine 10mg once daily, in a 12-week, randomised, double-blind trial in patients with mild to moderate hypertension who had previously not responded to 4 weeksʼ treatment with lercanidipine.▴ In a similarly designed trial, lercanidipine/enalapril 10mg/20mg once daily was significantly more effective than enalapril 20mg once daily in hypertensive patients who had previously not responded to enalapril monotherapy.▴ Fixed-dose lercanidipine/enalapril was generally well tolerated, with a tolerability profile similar to that of either of the individual drugs alone or placebo. Cough was reported in ≤5.2% and peripheral oedema in ≤1.5% of lercanidipine/enalapril recipients.(Table is included in full-text article.)
ACCESSION #
23684644

 

Related Articles

  • Decitabine in Myelodysplastic Syndromes: A Viewpoint by Guillermo Garcia-Manero. Garcia-Manero, Guillermo // Drugs;2006, Vol. 66 Issue 7, p959 

    â–´ Delapril/manidipine 30mg/10mg is a new oral, once-daily, fixed combination of an ACE inhibitor and a dihydropyridine calcium-channel antagonist for the treatment of essential hypertension.â–´ In a dose-finding study in 400 patients with mild to moderate hypertension,...

  • Decitabine in Myelodysplastic Syndromes: A Viewpoint by Hussain Saba. Saba, Hussain // Drugs;2006, Vol. 66 Issue 7, p959 

    â–´ Delapril/manidipine 30mg/10mg is a new oral, once-daily, fixed combination of an ACE inhibitor and a dihydropyridine calcium-channel antagonist for the treatment of essential hypertension.â–´ In a dose-finding study in 400 patients with mild to moderate hypertension,...

  • Delapril/Manidipine. McCormack, Paul L.; Keating, Gillian M. // Drugs;2006, Vol. 66 Issue 7, p961 

    â–´ Delapril/manidipine 30mg/10mg is a new oral, once-daily, fixed combination of an ACE inhibitor and a dihydropyridine calcium-channel antagonist for the treatment of essential hypertension.â–´ In a dose-finding study in 400 patients with mild to moderate hypertension,...

  • Physicians must individualize hypertension treatment. Zablocki, Elaine // Managed Healthcare Executive;May2004, Vol. 14 Issue 5, p52 

    Reports on the need to individualize the treatment for hypertension. Different classes of drugs that control hypertension; Advantage of diuretics over calcium channel blocker, and angiotensin-converting enzyme (ACE) inhibitor; Efficacy of ACE inhibitors in hypertensive patients with left...

  • INHIBITING CALCIUM CHANNEL BLOCKER-INDUCED PERIPHERAL EDEMA. Hoda, Tahirul // Cortlandt Forum;10/25/2004, Vol. 17 Issue 10, p63 

    This article presents an advisory related to the inhibition of calcium channel blocker-induced peripheral edema. Adding an ACE inhibitor will reduce peripheral edema caused by calcium channel blockers. Diuretics can reduce the peripheral edema of calcium blockers regardless of the mechanism of...

  • Serum Calcium Level in Hypertension. Hazari, Mohammed Abdul Hannan; Arifuddin, Mehnaaz Sameera; Muzzakar, Syed; Reddy, Vontela Devender // North American Journal of Medical Sciences;Nov2012, Vol. 4 Issue 11, p569 

    Background: The alterations in extracellular calcium level may influence intracellular calcium level and possibly play a role in the pathogenesis of essential hypertension. Aim: The purpose was to find out the association between serum calcium levels and hypertension; and to compare the serum...

  • ACE Inhibitors vs. Calcium Antagonists in Reducing Stroke. Walling, Anne D. // American Family Physician;6/15/2001, Vol. 63 Issue 12, p2458 

    Presents information on a study by the international Blood Pressure Lowering Treatment Trialists' Collaboration to estimate the benefits of angiotensin-converting enxyme (ACE) inhibitors and other medications for the reduction of stroke. Description of the study and its results; Conclusion that...

  • Coupling of L-type calcium channels to neurotransmitter release at mouse motor nerve terminals. Urbano, Francisco J.; Depetris, Rafael S.; Uchitel, Osvaldo D. // Pflugers Archiv European Journal of Physiology;Mar2001, Vol. 441 Issue 6, p824 

    Previously, we have presented evidence for the presence of L-type voltage-dependent Ca2+ channels (VDCC) in 1,2-bis(2-aminophenoxy)ethane-N,N,N′,N′-tetraacetic acid, (acetoxymethyl)ester (BAPTA-AM)-incubated motor nerve terminals (MNTs) of the levator auris muscle of mature mice. The...

  • MY ABCD ALTERNATIVE. Kaul, Gulshan // Pulse;3/23/2006, Vol. 66 Issue 12, p47 

    The article suggests an alternative model for hypertension management in Great Britain. For patients over 55 years old or black patients of any age, first choice of treatment is calcium channel blocker, with thiazide diuretic as alternative. The second treatment of choice is ACE inhibitor. For...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics